Ximbio has reached a new milestone since launch and is excited to announce that over 1000 research reagents are now listed on the website. This has been achieved by the newly registered Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC) and is an example of our growing international success.
IGBMC is a joint research unit of the University of Strasbourg, Inserm and CNRS. Based in Strasbourg, it is one of Europe's leading centres in biomedical research. Much of the work carried out at IGBMC involves the use of mouse models, zebrafish, yeast and drosophila to understand the biology of development and its involvement in human pathologies. The Institute has four departments, each composed of several teams with specific research themes including:
- Developmental Biology and Stem Cell Research Department
- Functional genomics and cancer
- Neurogenetics and Translational Medicine
- Integrative Structural biology
To date IGBMC have listed 180 reagents on Ximbio, most of which are monoclonal antibodies. These include widely adopted antibodies to the Huntingtin protein, linked to the neurodegenerative disorder Huntington's disease in addition to antibodies specific for the polyglutamine-expansion caused by a CAG repeat found in several neurodegenerative diseases including spinocerebellar ataxia type 2, 3 and 7.
The addition of these research tools demonstrates how the Ximbio reagent portfolio is diversifying beyond cancer research. Over the last five months, more than 260 reagents have been added to the portfolio that originate from various research fields including but not limited to:
These achievements contribute to our core mission; to unify the reagent community and make tools more widely accessible in order to accelerate life science research.